On. Target Molecules Biotech Inc has created a novel technology platform to accelerate advancements in cancer therapeutics. The company is commencing detailed pre-clinical studies, including IND-enabling studies, to develop, obtain regulatory approval for, and commercialize many variations of its sequenced and patented monoclonal antibodies against all indications of cancer.
We are in the process of developing our anti-cancer molecule for several cancers; which include Melanoma, Breast, Bladder, Cervical, Liver, Prostate, and Glioblastoma Cancer. The Architecture of the Fusion Protein is the key that locks onto a Bio-marker expressed in Cancer Cells. The antibody causes apoptosis at 75% in 7 days.
O.TM Biotech Antibody in Action Images of Cancer Cells at O.TM Biotech's Research Facility
These images from tests conducted at our lab show Cancer Cells undergoing Apoptosis ( natural cell death) on treatment with the O.TM Biotech Antibody.
An overview of the efficacy of O.TM Biotech’s antibody which causes an average Apoptosis (natural cell death) at 75 % in 7 days with two doses in-vitro. O.TM Biotech has produced molecules of high caliber tested on 24 cancer cell lines with great results.
An Overview of the Research Work at O.TM Biotech
O. TM Biotech plans to bio-engineer anti cancer molecules in a relatively short span of time
O.TM Biotech has used innovative techniques, ingenuity, and cutting edge technologies to engineer its novel antibody to cause natural cell death in several cancer cell lines. Currently three variable sequences leading to eight therapeutically significant and viable drug products are in the pipeline. Building on the success to date, O.TM Biotech is poised to take on the remaining phases in its fight against cancer at scale and speed.
PRODUCT DEVELOPMENT IN THE PIPELINE
Biodegradable and bio-compatible polymer mimics of molecules that target cancer bio-markers.
Develop molecularity imprinted polymers designed to have molecular recognition to the biologic template.
The polymer formulating machine and the imprint process leading to sensors and therapeutic mimics are in the process of IP filing
Nanoparticles which target cancer cells act as antennae for RF from a RF device and ablate cells. The RF ablation IP surrounds the RF machine and the nanoparticles which act as heat flux agents